Pfizer's Herceptin biosimilar candidate successful in late-stage study

|About: Pfizer Inc. (PFE)|By:, SA News Editor

A Phase 3 clinical trial, REFLECTIONS B3271002, comparing the safety and efficacy of Pfizer's (NYSE:PFE) biosimilar PF-05280014 to Roche's (OTCQX:RHHBY) Herceptin (trastuzumab) met the primary endpoint of showing equivalence as measured by objective response rate (ORR), taken in combination with paclitaxel, in first-line patients with HER-positive metastatic breast cancer.

A separate study, REFLECTIONS B3271004, in early breast cancer patients was also successful.

The development of PF-05280014 is ongoing. According to, there are four studies currently recruiting patients and five that are active with recruiting completed.